Metronidazole Ratiopharm (Metronidazole)

Metronidazole penetrates anaerobic microorganisms and is reduced at its nitro group, forming reactive nitro radicals. These radicals damage microbial DNA and inhibit nucleic acid synthesis, leading to cell death while sparing aerobic cells, which lack the necessary reduction environment.

The dosage of Metronidazole Ratiopharm is determined by the prescribing clinician based on the specific infection, patient age, weight, renal and hepatic function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare provider.

Safety data for Metronidazole during pregnancy are limited, so it should only be used if the potential benefit justifies the risk. The drug can be excreted in breast milk; therefore, breastfeeding mothers should discuss potential risks and benefits with their healthcare professional before use.

To order Metronidazole Ratiopharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic bacteria and certain protozoa, offering a broad spectrum for these organisms. Compared with beta‑lactam antibiotics, it provides effective coverage without the need for beta‑lactamase inhibitors, but it lacks activity against aerobic organisms, so choice depends on the suspected pathogen profile.

Metronidazole Ratiopharm should be stored at room temperature below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metronidazole Ratiopharm is administered orally, typically as a tablet taken with water. The exact timing (with or without food) and frequency are determined by the prescribing clinician based on the infection being treated and patient-specific factors.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, pseudomembranous colitis, and hepatotoxicity. Patients should seek immediate medical attention if they experience neurological symptoms, severe skin reactions, or signs of liver injury.

Metronidazole Ratiopharm should be avoided in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic or renal impairment, and it should not be used concurrently with alcohol due to the risk of a disulfiram‑like reaction.